With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

Explore the case of Joanne Chesimard, also known as Assata Shakur, a controversial figure convicted of killing a New Jersey ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...

Former Baloch Liberation Army commander Najibullah, alongside other ex-militants, renounced violence and revealed foreign agencies' role in supporting Baloch separatists. Speaking in Quetta with ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...